Letters “Breakthrough” drug in Alzheimer’s disease

Author’s reply to Karran

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4532 (Published 01 September 2015) Cite this as: BMJ 2015;351:h4532
  1. Margaret McCartney, general practitioner1
  1. 1Glasgow, UK
  1. margaret{at}margaretmccartney.com

Karran says that the EXPEDITION and EXPEDITION 2 trials showed a 34% slowing of cognitive decline—evidence of a disease modifying effect.1 2

He did not reference this statement and on PubMed I found only a short presentation (“oral session,” apparently from the Alzheimer’s Association International Conference 2013).3 The results read “In the mild population, approximately 34% less cognitive decline (ADAS-Cog 11, ADAS-Cog 14, and MMSE) …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe